Hempel H et al. The importance of using WHO International standards to harmonise SARS-CoV-2 serological assays. Lancet Microbe, 2024. 5(3).

Fry SR, et al. The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach. PLoS Negl Trop Dis. 2011;5(6):e1199.

Article  PubMed  PubMed Central  Google Scholar 

Conklin SE et al. Evaluation of Serological SARS-CoV-2 lateral Flow assays for Rapid Point-of-care testing. J Clin Microbiol, 2021. 59(2).

Wagenhäuser I, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine. 2021;69:103455.

Article  PubMed  PubMed Central  Google Scholar 

Lai SC, et al. Development of Novel Dengue NS1 Multiplex lateral Flow Immunoassay to differentiate serotypes in serum of Acute Phase patients and infected mosquitoes. Front Immunol. 2022;13:852452.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Falconar AK, Romero-Vivas CM. A simple, inexpensive, robust and sensitive dot-blot assay for equal detection of the nonstructural-1 glycoprotein of all dengue virus serotypes. Virol J. 2013;10:126.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kodani M et al. An automated immunoblot method for detection of IgG antibodies to Hepatitis C Virus: a potential supplemental antibody confirmatory assay. J Clin Microbiol. 2019;57(3).

Nascimento EJM, et al. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018;257:48–57.

Article  CAS  PubMed  Google Scholar 

Mishra N et al. Diagnosis of Zika Virus infection by peptide array and enzyme-linked immunosorbent assay. mBio. 2018;9(2).

Okba NMA, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific antibody responses in Coronavirus Disease patients. Emerg Infect Dis. 2020;26(7):1478–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo L, et al. Profiling early humoral response to diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;71(15):778–85.

Article  CAS  PubMed  Google Scholar 

Matsunaga KI, et al. Competitive ELISA for a serologic test to detect dengue serotype-specific anti-NS1 IgGs using high-affinity UB-DNA aptamers. Sci Rep. 2021;11(1):18000.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Acharya D, et al. An ultrasensitive electrogenerated chemiluminescence-based immunoassay for specific detection of Zika virus. Sci Rep. 2016;6:32227.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lau CS, et al. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay. Clin Chim Acta. 2020;510:760–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lippi G, Henry BM, Adeli K. Diagnostic performance of the fully automated Roche Elecsys SARS-CoV-2 antigen electrochemiluminescence immunoassay: a pooled analysis. Clin Chem Lab Med. 2022;60(5):655–61.

Article  CAS  PubMed  Google Scholar 

Peeling RW, et al. Serology testing in the COVID-19 pandemic response. Lancet Infect Dis. 2020;20(9):e245–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan KR, et al. Serological cross-reactivity among common flaviviruses. Front Cell Infect Microbiol. 2022;12:975398.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Low SL, et al. Evaluation of eight commercial Zika virus IgM and IgG serology assays for diagnostics and research. PLoS ONE. 2021;16(1):e0244601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health Organization. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. World Health Organization: Geneva; 2007.

Google Scholar 

Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ella R, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tebas P, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2021;31:100689.

Article  PubMed  Google Scholar 

Padoan A, et al. SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays. Clin Chim Acta. 2021;523:446–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lau EHY, et al. Neutralizing antibody titers in SARS-CoV-2 infections. Nat Commun. 2021;12(1):63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Padoan A, et al. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Clin Chem Lab Med. 2022;60(3):456–63.

Article  CAS  PubMed  Google Scholar 

Low SL, et al. Dengue seroprevalence of healthy adults in Singapore: serosurvey among blood donors, 2009. Am J Trop Med Hyg. 2015;93(1):40–5.

Article  PubMed  PubMed Central  Google Scholar 

Sasmono RT, et al. Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia. PLoS Negl Trop Dis. 2018;12(6):e0006616.

Article  PubMed  PubMed Central  Google Scholar 

Murhekar MV, et al. Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey. Lancet Glob Health. 2019;7(8):e1065–73.

Article  PubMed  Google Scholar 

Limkittikul K, et al. Dengue virus seroprevalence study in Bangphae district, Ratchaburi, Thailand: a cohort study in 2012–2015. PLoS Negl Trop Dis. 2022;16(1):e0010021.

Article  PubMed  PubMed Central  Google Scholar 

Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health Organization. Dengue and severe dengue. 2023 23/08/2023]; https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

John S. A.L., Adaptive immune responses to primary and secondary dengue virus infections. Nat Rev Immunol 2019 19:4, 2019. 19(4).

Mansfield KL, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92(Pt 12):2821–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rathore APS, St John AL. Cross-Reactive Immun among Flaviviruses Front Immunol. 2020;11:334.

CAS  Google Scholar 

Limothai U, et al. Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area. PLoS ONE. 2021;16(9):e0257182.

Article  CAS  PubMed  PubMed Central